Lilly presents new data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026
Lilly will present Phase 2 data showing EloraTZP achieved an average weight loss of 54.1 lbs (23.3%) and lowered A1C by 2.9% in adults with obesity or overweight and type 2 diabetes. Retatrutide results from TRIUMPH trials demonstrated reductions in apnea-hypopnea index and knee osteoarthritis pain up to 36.1 events per hour and 4.5 points, respectively.
Primary source
Company press release (PR Newswire), November 14, 2026
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Machine-summarized from the source above; not independently reported. How we use automation